BioCentury
ARTICLE | Strategy

You better you bet

How Achillion's HCV assets fit with J&J

May 25, 2015 7:00 AM UTC

Johnson & Johnson's deal with Achillion Pharmaceuticals Inc. ties up one of the last remaining and most advanced unpartnered HCV portfolios and gives the pharma what could be a best-in-class molecule to catch up in the race for a short-duration pan-genotypic regimen.

Despite near-simultaneous approvals, J&J is a distant second in terms of market share behind Gilead Sciences Inc. in the market for interferon-sparing regimens to treat HCV. ...